Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Cancer Genomics & Proteomics, December 2009
Al-Ruwaili JA, Larkin SE, Zeidan BA, Taylor MG, Adra CN, Aukim-Hastie CL, Townsend PA, JAMAL A. AL-RUWAILI, SAMANTHA ET. LARKIN, BASHAR A. ZEIDAN, MATTHEW G. TAYLOR, CHAKER N. ADRA, CLAIRE L. AUKIM-HASTIE, PAUL A. TOWNSEND
The incidence of prostate cancer (PCa) has increased in recent years due to the aging of the population and increased testing; however, mortality rates have remained largely unchanged. Studies have shown deficiencies in predicting patient outcome for both of the major PCa diagnostic tools, namely prostate specific antigen (PSA) and transrectal ultrasound-guided biopsy. Therefore, serum biomarkers are needed that accurately predict prognosis of PCa (indolent vs. aggressive) and can thus inform clinical management.
|Readers by professional status||Count||As %|
|Professor > Associate Professor||4||21%|
|Student > Ph. D. Student||3||16%|
|Student > Postgraduate||2||11%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||5||26%|
|Agricultural and Biological Sciences||5||26%|
|Biochemistry, Genetics and Molecular Biology||2||11%|